CDC25B 抗体

The CDC25B antibody is a critical tool for studying the CDC25B phosphatase, a member of the CDC25 family (CDC25A, B, C) that regulates cell cycle progression by activating cyclin-dependent kinases (CDKs). CDC25B specifically dephosphorylates CDK1 at inhibitory residues, driving the transition from G2 to M phase. Its dysregulation is linked to cancer, as overexpression can disrupt cell cycle checkpoints, promoting genomic instability and tumorigenesis. The antibody enables detection and quantification of CDC25B protein in various applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding research on its expression patterns in normal tissues and malignancies. Studies using CDC25B antibodies have revealed its prognostic value in cancers like breast, lung, and colorectal, where elevated levels correlate with poor outcomes. Additionally, these antibodies are instrumental in exploring CDC25B's role in drug resistance and as a therapeutic target. Commercially available CDC25B antibodies are typically raised against specific epitopes, with validation via knockout controls or peptide blocking to ensure specificity. Researchers prioritize antibodies with high sensitivity and minimal cross-reactivity to other CDC25 isoforms. As CDC25B inhibitors emerge in preclinical studies, reliable antibodies remain essential for mechanistic insights and translational applications in oncology and cell cycle biology.